Dublin, April 08, 2024 (GLOBE NEWSWIRE) -- The "Atypical Hemolytic Uremic Syndrome (aHUS) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
Market Overview and Growth Trajectory
A detailed report on Atypical Hemolytic Uremic Syndrome (aHUS) has been released, providing thorough understanding into the disease's epidemiology, market trends, and forecasted developments through 2032. Key findings indicate that the diagnosed cases of aHUS approached 4,800 in the 7 major markets (7MM) in 2022. This number is expected to see a growth with a compound annual growth rate (CAGR) of approximately 4% from 2019 to 2032.
aHUS Diagnostic and Therapeutic Insights
The disease, characterized by abnormal blood clots in small blood vessels, particularly affects the kidneys and can lead to severe complications, such as kidney failure. Diagnosis typically involves a complete blood count and specialized blood tests, including measuring eGFR levels for kidney function. The treatment landscape primarily features supportive care and plasma exchange; however, two complement inhibitor drugs, eculizumab and ravulizumab, are currently approved for aHUS treatment.
Emerging Therapies and Market Leaders
Emerging therapies, including those in late-stage development, are poised to transform the market. Prominent among them are iptacopan by Novartis and crovalimab by Roche. The United States continues to lead the market in size and is expected to contribute significantly to the market's growth. However, access to these high-priced innovative treatments remains a concern that impacts commercial uptake.
Current and Future Treatment Dynamics
The report highlights the transition of patients from eculizumab to ravulizumab, which is anticipated to reduce treatment frequency, leading to decreased costs and improved quality of life for patients. Despite the effectiveness of current treatments, their associated high costs often limit broader usage, underlining an urgent need for more accessible treatment options.
Consultation with Key Opinion Leaders (KOLs)
KOLs from varied institutions, including hospitals and universities across the 7MM regions, have provided valuable insights on current treatment practices, the evolving treatment landscape, and the challenges faced regarding drug accessibility and patient care. Their assessments have played a vital role in shaping the understanding of the aHUS market dynamics.
Overall, the report presents a comprehensive analysis, which is expected to be of significant interest to stakeholders in the healthcare and pharmaceutical sectors, aiding in strategic planning and decision-making to improve patient outcomes in the management of aHUS.
Key Topics Covered:
- Key Insights
- Report Introduction
- Atypical Hemolytic Uremic Syndrome (aHUS) Market Overview at a Glance
- Executive Summary of Atypical Hemolytic Uremic Syndrome (aHUS)
- Key Events
- Epidemiology and Market Forecast Methodology
- Disease Background and Overview
- Current Treatment Practices of aHUS
- Patient Journey
- Epidemiology and Patient Population
- Marketed Therapies
- Emerging Therapies
- Atypical Hemolytic Uremic Syndrome (aHUS): Seven Major Market Analysis
- Unmet Needs
- SWOT Analysis
- KOL Views
- Market Access and Reimbursement
- Appendix
- Publisher Capabilities
- Disclaimer
A selection of companies mentioned in this report includes, but is not limited to:
- Novartis Pharmaceuticals
- Hoffmann-La Roche
- Chugai Pharmaceutical
For more information about this report visit https://www.researchandmarkets.com/r/bwbvld
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
